WASHINGTON, D.C. (January 23, 2014) – The Biotechnology Industry Organization (BIO) today announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 16th annual BIO CEO & Investor Conference. Moderators and panelists for this premier represent industry thought leaders, academics and biopharma executives. The conference is to be held in New York City, February 10-11, 2014, and is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.
“Given the outstanding performance of biotech equities over the past few years, we see a surge in investor interest in our sector as evidenced by the uptick in pre-event investor registration for our exclusive event. The BIO CEO & Investor Conference serves a vital role in bringing industry leaders together and generating the investment support that helps to fuel groundbreaking R&D and ultimately breakthrough technologies,” said BIO President & CEO Jim Greenwood. “This year's program will feature biotech, pharma and Wall Street leaders sharing their candid insights on what to expect in 2014 and beyond.”
In addition to the five Fireside Chats with top biopharma CEOs, the BIO CEO & Investor Conference will feature timely discussions with industry experts on a variety of topics.
The Plenary Sessions will address the upcoming year, using the results of the joint BIO / ISI published Buy-Side Perception Study as well as dissect the new capital market environment’s impact on fundraising.
Plenary sessions include:
· Opening Plenary: A Room with a (Buy-Side) View: The Year Ahead
· Closing Plenary: Fundraising in the New Capital Market Environment
Business Roundtables include:
· The Reimbursement Landscape Under ACA
· Let’s Make a Deal – Strategic Licensing and M&A Trends
· Solution Development: Aiming the Whole Pipeline at a Single Goal
Therapeutic Workshops include:
· Delivering the [RNAi] Goods
· Keeping an I on Oncology: The ASCO Immunotherapy Preview
· Balancing the Risk-Reward in Rare Disease Drug Development
In addition, attendees have access to BIO’s One-on-One Partnering™ System which provides the opportunity to arrange meetings between and among investors, companies and industry executives. Further, the event features presentations from more than 150 leading biotechnology and pharmaceutical companies.
Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors.
Media registration also is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO is pleased to recognize the leadership provided by the sponsors of the BIO CEO & Investor Conference, including supporting banks H.C. Wainwright & Co., JMP Securities, Lazard, Leerink Partners LLC and ROTH Capital Partners, LLC.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter.” Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY
BIO Asia International Conference
April 8-9, 2014
World Congress on Industrial Biotechnology
May 12-15, 2014
BIO International Convention
June 23-26, 2014
San Diego, CA
Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD